Jooste V, Nousbaum JB, Alves A, Woronoff AS, Launoy G, Molinié F, Desandes E, Delafosse P, Tretarre B, Mercier E, Lepage C, Ghiringhelli F, Bouvier AM,

JAMA Netw Open. 2025 11 3;8(11):e2541732

Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.

Ambrosini M, Blons H, Garinet S, Mulot C, Le Corre D, Mouillet-Richard S, Pietrantonio F, Sroussi M, Lepage C, Laurent-Puig P, Taieb J

ESMO Open. 2025 10 29;10(11):105857

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer.

Lepage C, Phelip JM, Cany L, Barbier E, Manfredi S, Deguiral P, Laly M, Baconnier M, Jary M, Latrive JP, Terrebonne E, Lièvre A, Jafari M, Ben Abdelghani M, Ain JF, Breysacher G, Boillot-Benedetto I, Pelaquier A, Prost P, Ezenfis J, Rinaldi Y, Le Foll C, Berthelet O, Darut-Jouve A, Dahan L, Piche T, Lagasse JP, Bibeau F, Laurent-Puig P, Bouché O,

Ann Oncol. 2025 09 17;:

Accounting for Misclassification of Binary Outcomes in External Control Arm Studies for Unanchored Indirect Comparisons: Simulations and Applied Example.

Nourredine M, Gavoille A, Lepage C, Kassai-Koupai B, Cucherat M, Subtil F

Stat Med. 2025 09;44(20-22):e70236

Deep learning on histological slides accurately predicts Consensus Molecular Subtypes and spatial heterogeneity in colon cancer.

LE Douget JE, Jacob P, Lepage C, Gallois C, Sroussi M, Reynies ADE, Cazelles A, Gonzalez D, Maussion C, Bouche O, Levache CB, Jary M, Mineur L, Jegou S, Saillard C, Morel M, Taïeb J, Bibeau F, Emile JF, Laurent-Puig P

Mod Pathol. 2025 08 25;:100877

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI).

Tougeron D, Mineur L, Zaanan A, Kadi M, Poisson Ligeza C, Bourgeois V, Martin-Babau J, Fadin A, Jestin le Tallec V, Ly Lebrun V, Dubreuil O, Khemissa Akouz F, Thimonier E, Bouché O, Lièvre A, Di Fiore F, Lecomte T, Lepage C, Hautefeuille V,

Eur J Cancer. 2025 08 22;228:115741

The impact of cancer survivors' extra risk of non-cancer mortality on net survival estimation.

Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Maso LD, Lepage C, Molinié F, Bouvier AM, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V, Wg TE

Am J Epidemiol. 2025 08 19;:

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.

Bergen ES, Canton C, Boulin M, Le Malicot K, Bennouna J, Gonzalez D, Mineur L, Bouche O, Lepage C, Taieb J

Eur J Cancer. 2025 07 12;227:115643

Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Assenat E, Ben Abdelghani M, Gourgou S, Perrier H, Akouz FK, Desgrippes R, Galais MP, Janiszewski C, Mazard T, Rinaldi Y, Lepage C, Tetreau R, Senesse P

J Clin Oncol. 2025 06 20;:JCO2402754

Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.

Ganame S, Walter T, Durand A, Lièvre A, Tougeron D, Scoazec JY, Baudin E, Lepage C, Boussari O, Hadoux J

Eur J Cancer. 2025 04 30;:115450

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.

Tougeron D, Louvet C, Desramé J, Evesque L, Angelergues A, Carnot A, Breysacher G, Zaanan A, Etchepare N, Mabro M, Kaluzinski L, Petorin C, Chibaudel B, Aparicio T, Bodere A, Rinaldi Y, Le Malicot K, Emile JF, Lepage C, Baures A, Djamai H, Taly V, Laurent-Puig P

Commun Med (Lond). 2025 04 24;5(1):136

A Randomized clinical trial evaluating the impact on survival and quality of life of Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A

BMC Cancer. 2025 04 4;25(1):613

What are the outcomes for long-term survivors after esophagectomy ? - Evidence from a randomized controlled trial (FFCD9901).

Robb WB, Veziant J, Dahan L, Mornex F, Barbier E, D'Journo XB, Manfredi S, Boige V, Jary M, Christou N, Lepage C, Piessen G,

Eur J Surg Oncol. 2025 03 6;51(7):109736

Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).

Lecomte T, Giraudeau B, Phelip JM, Tournigand C, Ducreux M, Tougeron D, Lepage C, Mineur L, Laplaige P, Desgrippes R, Artru P, Borg C, Jary M, Bouché O, Metges JP, Guimbaud R, Aparicio T, Foubert F, Hautefeuille V, Muller M, Bouhier-Leporrier K, Darrius R, Lobet S, Monmousseau F, Bejan-Angoulvant T, Paintaud G, Ternant D

Dig Liver Dis. 2025 03 4;:

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.

Gallois C, Sroussi M, André T, Mouillet-Richard S, Agueeff N, Mulot C, Vernerey D, Louvet C, Bachet JB, Dourthe LM, Mazard T, Jary M, Coutzac C, Lecaille C, Tabernero J, Van Laethem JL, Lepage C, Emile JF, de Reyniès A, Taieb J, Laurent-Puig P

J Clin Oncol. 2025 01 31;:JCO2302262

Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study.

Dabout V, Mineur L, Tougeron D, Malicot KL, Gallois C, Phelip JM, Turpin A, Cohen R, Demoustier B, Hautefeuille V, Locher C, Levaché CB, Mitry E, Lecomte T, Brocard F, Hassid D, Porte M, Breysacher G, Lagasse JP, Lepage C, Valéry M, Bachet JB

Clin Res Hepatol Gastroenterol. 2024 12 12;:102514

Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer.

Fumet JD, Roussot N, Bertaut A, Limagne E, Thibaudin M, Hervieu A, Zanetta S, Borg C, Senellart H, Pernot S, Thuillier F, Carnot A, Mineur L, Chibaudel B, Touchefeu Y, Martin-Babau J, Jary M, Labourey JL, Rederstorff E, Lepage C, Ghiringhelli F

Future Oncol. 2024 11 12;:1-9

[Targeted therapies and immunotherapy: Positioning in the field of innovation and challenges for the therapeutic decision-making process].

El Chami C, Meunier-Beillard N, Binquet C, Lepage C, Lejeune C

Bull Cancer. 2024 08 28;:

Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.

Fosse A, Hadoux J, Girot P, Beron A, Afchain P, Cottereau AS, Baudin E, Dierickx LO, Lecomte T, Perrier M, Lepage C, Bouhier-Leporrier K, Goichot B, Lachachi B, Walter T, Durand A

J Nucl Med. 2024 08 1;:

Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE.

Buchalet C, Lemanski C, Pommier P, Le Malicot K, Bonichon-Lamichhane N, Evesque L, Diaz O, Ronchin P, Quero L, Campo ERD, Tougeron D, Salas S, Bengrine-Lefevre L, Lepage C, Vendrely V

Dig Liver Dis. 2024 07 12;:

Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.

Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Maso LD, Lepage C, Molinié F, Bouvier AM, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V,

Eur J Cancer. 2024 07 9;208:114187

Trends in incidence of infrequent and frequent synchronous metastases from colorectal cancer.

Jooste V, Lepage C, Manfredi S, Bouvier AM

Dig Liver Dis. 2024 07 6;:

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3).

de Rauglaudre B, Piessen G, Jary M, Le Malicot K, Adenis A, Mazard T, D'Journo XB, Petorin C, Buffet-Miny J, Aparicio T, Guimbaud R, Vendrely V, Lepage C, Dahan L

Clin Transl Radiat Oncol. 2024 07;47:100804

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Martin E, Le Malicot K, Guérin-Charbonnel C, Bocquet F, Bouché O, Turpin A, Aparicio T, Legoux JL, Dahan L, Taieb J, Lepage C, Dourthe LM, Pétorin C, Bourgeois V, Raoul JL, Seegers V

Curr Oncol. 2024 06 17;31(6):3513-3528

Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts.

Lecuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Emile JF, Bibeau F, Taïeb J, Derangere V, Lepage C, Ghiringhelli F

EBioMedicine. 2024 06 15;105:105207

Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.

Chevalier B, Bonnet D, Lepage C, Perrier M, Borson-Chazot F, Abeillon J, Delobel JB, Jannin A, Hadoux J, Haissaguere M, Lombard-Bohas C, Walter T, Chardon L

J Endocr Soc. 2024 05 23;8(7):bvae102

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Boisteau E, Dahan L, Williet N, Le Malicot K, Desramé J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Lepage C, Granger V, Legoux JL, Deplanque G, Baconnier M, Lecomte T, Bonnet I, Seitz JF, François E, Lièvre A,

Oncologist. 2024 05 4;:

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).

Legoux JL, Faroux R, Barrière N, Le Malicot K, Tougeron D, Lorgis V, Guerin-Meyer V, Bourgeois V, Malka D, Aparicio T, Baconnier M, Lebrun-Ly V, Egreteau J, Khemissa Akouz F, Terme M, Lepage C, Boige V

Cancers (Basel). 2024 04 16;16(8):

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C,

JAMA Oncol. 2024 04 4;:

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).

Roth GS, Verlingue L, Sarabi M, Blanc JF, Boleslawski E, Boudjema K, Bretagne-Bignon AL, Camus-Duboc M, Coriat R, Créhange G, De Baere T, de la Fouchardière C, Dromain C, Edeline J, Gelli M, Guiu B, Horn S, Laurent-Croise V, Lepage C, Lièvre A, Lopez A, Manfredi S, Meilleroux J, Neuzillet C, Paradis V, Prat F, Ronot M, Rosmorduc O, Cunha AS, Soubrane O, Turpin A, Louvet C, Bouché O, Malka D

Eur J Cancer. 2024 03 13;202:114000

Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR).

Lecomte T, Tougeron D, Chautard R, Bressand D, Bibeau F, Blanc B, Cohen R, Jacques J, Lagasse JP, Laurent-Puig P, Lepage C, Lucidarme O, Martin-Babau J, Panis Y, Portales F, Taieb J, Aparicio T, Bouché O, ,,,,,,,,,,,

Dig Liver Dis. 2024 02 20;:

Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.

Perrier M, Brugel M, Gérard L, Goichot B, Lièvre A, Lepage C, Hautefeuille V, Do Cao C, Smith D, Thuillier P, Cros J, Cadiot G, Walter T, de Mestier L

Eur J Endocrinol. 2023 12 1;:

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

Rasola C, Laurent-Puig P, André T, Falcoz A, Lepage C, Aparicio T, Bouché O, Lievre A, Mineur L, Bennouna J, Louvet C, Bachet JB, Borg C, Vernerey D, Lonardi S, Taieb J

Eur J Cancer. 2023 09 9;194:113321

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.

Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D,

JAMA Oncol. 2023 08 3;:

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Ben Abdelghani M, Lepage C, Aparicio T,

Radiother Oncol. 2023 06 12;:109742

Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site.

Ghiringhelli F, Jooste V, Manfredi S, Hennequin A, Lepage C, Bouvier AM

HPB (Oxford). 2023 06;25(6):693-703

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.

Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB

J Gastrointest Oncol. 2023 04 29;14(2):997-1007

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Gronnier C, Mariette C, Lepage C, Monterymard C, Jary M, Ferru A, Baconnier M, Adhoute X, Tavan D, Perrier H, Guerin-Meyer V, Lecaille C, Bonichon-Lamichhane N, Pillon D, Cojocarasu O, Egreteau J, D'journo XB, Dahan L, Locher C, Texereau P, Collet D, Michel P, Ben Abdelghani M, Guimbaud R, Muller M, Bouché O, Piessen G

Cancers (Basel). 2023 04 6;15(7):

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE.

Vendrely V, Lemanski C, Pommier P, LE Malicot K, Saint A, Rivin Del Campo E, Regnault P, Baba-Hamed N, Ronchin P, Crehange G, Tougeron D, Menager-Tabourel E, Diaz O, Hummelsberger M, Minsat M, Drouet F, Larrouy A, Peiffert D, Lievre A, Zasadny X, Hautefeuille V, Mornex F, Lepage C, Quero L,

Radiother Oncol. 2023 02 20;:109542

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.

Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C

Lancet Oncol. 2023 02 2;:

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

Salfati D, Huot M, Aparicio T, Lepage C, Taieb J, Bouché O, Boige V, Phelip JM, Dahan L, Bennouna J, Le Malicot K, Boussari O, Gornet JM

Dig Liver Dis. 2023 01 30;:

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies and as Risk Recurrence Factors in Stage II Colon Cancer.

Tournier B, Aucagne R, Truntzer C, Fournier C, Ghiringhelli F, Chapusot C, Martin L, Bouvier AM, Manfredi S, Jooste V, Callanan MB, Lepage C

Cancers (Basel). 2022 12 27;15(1):

Repeat Element Activation-Driven Inflammation: Role of NFκB and Implications in Normal Development and Cancer?

Dumetier B, Sauter C, Hajmirza A, Pernon B, Aucagne R, Fournier C, Row C, Guidez F, Rossi C, Lepage C, Delva L, Callanan MB

Biomedicines. 2022 12 1;10(12):

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.

Manfredi S, Dior M, Bouche O, Barbier E, Hautefeuille V, Guillet M, Turpin J, Bourgeois V, Helene DO, Desgrippes R, Audemar F, Molin Y, Locher C, Chatellier T, Lecomte T, Baize N, Lecaille C, Spaeth D, Goujon G, Lepage C, Tougeron D,

Cancer Med. 2022 11 16;:

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer.

Grancher A, Beaussire L, Manfredi S, Le Malicot K, Dutherage M, Verdier V, Mulot C, Bouché O, Phelip JM, Levaché CB, Deguiral P, Coutant S, Sefrioui D, Emile JF, Laurent-Puig P, Bibeau F, Michel P, Sarafan-Vasseur N, Lepage C, Di Fiore F

Front Oncol. 2022 11 10;12:973167

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T

Eur J Cancer. 2022 09 7;175:31-40

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.

Kerckhove N, Tougeron D, Lepage C, Pezet D, Le Malicot K, Pelkowski M, Pereira B, Balayssac D

BMC Cancer. 2022 07 7;22(1):742

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F,

Eur J Cancer. 2022 07 1;172:221-230

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.

Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, Tougeron D, On Behalf Of The Durigast-Prodige Investigators/Collaborators

Biomedicines. 2022 05 23;10(5):

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.

Randrian V, Pernot S, Le Malicot K, Catena V, Baumgaertner I, Tacher V, Forestier J, Hautefeuille V, Tabouret-Viaud C, Gagnaire A, Mitry E, Guiu B, Aparicio T, Smith D, Dhomps A, Tasu JP, Perdrisot R, Edeline J, Capron C, Cheze-Le Rest C, Emile JF, Laurent-Puig P, Bejan-Angoulvant T, Sokol H, Lepage C, Taieb J, Tougeron D

Dig Liver Dis. 2022 05 21;:

Lichenoid eruption during antiPD-L1 immunotherapy with avelumab in metastatic colorectal cancer.

Brayer M, Lepage C, Taieb J, Tougeron D

Clin Res Hepatol Gastroenterol. 2022 Apr 21;:101924

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.

Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C

Adv Ther. 2022 Apr 13;:

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.

Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D, Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C, Lièvre A

Dig Liver Dis. 2022 Mar 26;:

Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice.

Jooste V, Bengrine-Lefevre L, Manfredi S, Quipourt V, Grosclaude P, Facy O, Lepage C, Ghiringhelli F, Bouvier AM

Cancers (Basel). 2022 Mar 25;14(7):

Impact of G-CSF Prophweylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.

Canton C, Boussari O, Boulin M, Le Malicot K, Taieb J, Dahan L, Lopez A, Lepage C, Bachet JB

Oncologist. 2022 Mar 15;:

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.

Christou N, Bergen ES, Canton C, Le Malicot K, Di Bartolomeo M, Galli F, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J

Eur J Cancer. 2022 Mar 10;166:100-111

A colonoscopy quality improvement intervention in an endoscopy unit.

Palmier R, Degand T, Aho S, Lepage C, Facy O, Michiels C, Manfredi S

Sci Rep. 2022 Jan 17;12(1):817

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.

Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B, Gallois C, Khemissa Akouz F, De Baere T, Tougeron D, Thirot-Bidault A, Audemar F, Simon M, Lecaille C, Louafi S, Lepage C, Ducreux M, Taieb J

Dig Liver Dis. 2022 Jan 10;:

Surveillance of colorectal cancers following curative-intent surgery: "Whatever the cost?"

Lepage C, Bouché O, Phelip JM

Dig Liver Dis. 2022 Jan 10;:

[Rectal cancers resected for cure: monitoring, secondary prevention and late complications].

Lepage C

Rev Prat. 2022 Jan;72(1):55-60

Efficacy of treatments for VIPoma: A GTE multicentric series.

Brugel M, Walter T, Goichot B, Smith D, Lepage C, Cao CD, Hautefeuille V, Rebours V, Cadiot G, de Mestier L,

Pancreatology. 2021 Aug 5;:

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.

Dahan L, Williet N, Le Malicot K, Phelip JM, Desrame J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Seitz JF, Lepage C, François E,

J Clin Oncol. 2021 Jul 21;:JCO2003329

Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.

Gallois C, Emile JF, Kim S, Monterymard C, Gilabert M, Bez J, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Coriat R, Legoux JL, Hautefeuille V, Phelip JM, Lecomte T, Sokol H, Capron C, Randrian V, Lepage C, Lomenie N, Kurtz C, Taieb J, Tougeron D

Dig Liver Dis. 2021 Jun 29;:

Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences.

Marref I, Romain G, Jooste V, Vendrely V, Lopez A, Faivre J, Gerard JP, Bouvier AM, Lepage C

Dig Liver Dis. 2021 Jun 27;:

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.

Marisa L, Blum Y, Taieb J, Ayadi M, Pilati C, Le Malicot K, Lepage C, Salazar R, Aust D, Duval A, Blons H, Taly V, Gentien D, Rapinat A, Selves J, Mouillet-Richard S, Boige V, Emile JF, de Reyniès A, Laurent-Puig P

Clin Cancer Res. 2021 Jun 24;:

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial.

Voron T, Karoui M, LoDico R, Malicot KL, Espin E, Cianchi F, Jürgen W, Buggenhout A, Bruzzi M, Denimal F, Cazelles A, Douard R, Lepage C, Taieb J

Dig Liver Dis. 2021 Jun 8;:

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.

Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V, Monterymard C, Lorgis V, Thuillier F, Baudin E, Scoazec JY, Lepage C, Desgrippes R

Dig Liver Dis. 2021 May 12;:

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.

Bacci M, Quero L, Barbier E, Parrot L, Juguet F, Pommier P, Bazire L, Etienney I, Baba-Hamed N, Spindler L, François E, Ronchin P, Campo ERD, Lemanski C, Lièvre A, Siproudhis L, Abramowitz L, Lepage C, Vendrely V

Dig Liver Dis. 2021 Apr 15;:

Chemotherapy of metastatic colon cancer in France: A population-based study.

Mas L, Bachet JB, Jooste V, Lepage C, Bouvier AM

Dig Liver Dis. 2021 Apr 14;:

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

Basile D, Gallois C, Puglisi F, Cohen R, Goere D, Aprile G, Lepage C, Laurent-Puig P, Maio MD, Lecomte T, Pernot S, Zaanan A, Taieb J

Clin Res Hepatol Gastroenterol. 2021 Mar 27;:101681

Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.

Legoux JL, Lombard-Bohas C, Brixi H, Le Malicot K, Lecomte T, Dahan L, Ruszniewski P, Mahamat-Abakar A, Etienne PL, Caroli-Bosc FX, Dominguez S, Paule B, Terrebonne E, Michel P, Lepage C, Choukroun G,

Clin Res Hepatol Gastroenterol. 2021 Mar 19;45(5):101572

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicenter trial.

Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J,

Colorectal Dis. 2021 Feb 13;:

MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.

Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V

Cancers (Basel). 2021 Jan 7;13(2):

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H, Evesque L, Laurent-Puig P, Emile JF, Bez J, Lepage C, Tougeron D

Dig Liver Dis. 2020 Dec 24;:

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D

Dig Liver Dis. 2020 Dec 21;:

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Tougeron D, Michel P, Lièvre A, Ducreux M, Gaujoux S, Guiu B, Huguet F, Lecomte T, Lepage C, Louvet C, Maggiori L, Mariani P, Aparicio T, Bouché O, ,,,,,,,,,

Dig Liver Dis. 2020 Dec 16;:

Giraud N, Aparicio T, Ronchin P, Bazire LA, Le Malicot K, Lemanski C, Mirabel X, Étienne PL, Lièvre A, Cacheux W, Darut-Jouve A, de la Fouchardière C, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Saut O, Vendrely V

Cancer Radiother. 2020 Oct;24(6-7):772-773

Bacci M, Quéro L, Barbier E, Parrot L, Pommier P, Bazire LA, Lepage C, Abramowitz L, ,Vendrely V

Cancer Radiother. 2020 Oct;24(6-7):790-791

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.

Manfredi S, Turpin A, Malka D, Barbier E, Laurent-Puig P, Zaanan A, Dahan L, Lièvre A, Phelip JM, Michel P, Hautefeuille V, Legoux JL, Lepage C, Tougeron D, Aparicio T

Dig Liver Dis. 2020 Oct;52(10):1143-1147

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR

Rinaldi Y, Pointet AL, Khemissa Akouz F, Le Malicot K, Wahiba B, Louafi S, Gratet A, Miglianico L, Laharie H, Bouhier Leporrier K, Thirot Bidault A, Texereau P, Coriat R, Terrebonne E, Gouttebel MC, Malka D, Bachet JB, Lepage C, Taieb J,

Eur. J. Cancer. 2020 Jul 2;136:25-34

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.

Turpin A, de Baere T, Heurgué A, Le Malicot K, Ollivier-Hourmand I, Lecomte T, Perrier H, Vergniol J, Sefrioui D, Rinaldi Y, Edeline J, Jouve JL, Silvain C, Becouarn Y, Dauvois B, Baconnier M, Debette-Gratien M, Deplanque G, Dharancy S, Lepage C, Hebbar M,

Clin Res Hepatol Gastroenterol. 2020 Jun 21;:

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).

Lapeyre-Prost A, Pernot S, Sigrand J, Le Malicot K, Mary F, Aparicio T, Dahan L, Caroli-Bosc FX, Lecomte T, Doat S, Marthey L, Desrame J, Lepage C, Taieb J

Clin Colorectal Cancer. 2020 Jun 12;:

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.

Pernot S, Pellerin O, Artru P, Montérymard C, Smith D, Raoul JL, De La Fouchardière C, Dahan L, Guimbaud R, Sefrioui D, Jouve JL, Lepage C, Tougeron D, Taieb J,

Br. J. Cancer. 2020 Jun 8;:

"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".

Taïeb J, Benhaim L, Laurent Puig P, Le Malicot K, Emile JF, Geillon F, Tougeron D, Manfredi S, Chauvenet M, Taly V, Lepage C, André T

Dig Liver Dis. 2020 May 29;:

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Di Fiore F, Bouché O, Lepage C, Sefrioui D, Gangloff A, Schwarz L, Tuech JJ, Aparicio T, Lecomte T, Boulagnon-Rombi C, Lièvre A, Manfredi S, Phelip JM, Michel P, ,,,,,,,,

Dig Liver Dis. 2020 May 14;:

The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection.

Blangero Y, Rabilloud M, Laurent-Puig P, Le Malicot K, Lepage C, Ecochard R, Taieb J, Subtil F

Biom J. 2020 Apr 28;:

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.

Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C, Falandry C, Norguet Monnereau E, Ben Abdelghani M, Smith D, Rinaldi Y, Père Verge D, Baize N, Maillard E, Dohan A, Des Guetz G, Pamoukdjian F, Lepage C

J Geriatr Oncol. 2020 Apr 22;:

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G,

Dig Liver Dis. 2020 Mar 28;:

Loss of SMARCB1 expression in colon carcinoma.

Melloul S, Mosnier JF, Masliah-Planchon J, Lepage C, Le Malicot K, Gornet JM, Edeline J, Dansette D, Texereau P, Delattre O, Laurent Puig P, Taieb J, J-F E

Cancer Biomark. 2020 Feb 14;:

Study of Small Intestinal Bacterial Overgrowth in a Cohort of Patients with Abdominal Symptoms Who Underwent Bariatric Surgery.

Mouillot T, Rhyman N, Gauthier C, Paris J, Lang AS, Lepers-Tassy S, Manfredi S, Lepage C, Leloup C, Jacquin-Piques A, Brindisi MC, Brondel L

Obes Surg. 2020 Feb 12;:

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

Aparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Bachet JB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F,

Br. J. Cancer. 2020 Feb 4;:

Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, Blanc J, Truntzer C, Desmoulins I, Ladoire S, Hennequin A, Favier L, Bengrine L, Vincent J, Hervieu A, Dusserre JG, Lepage C, Foucher P, Borg C, Albuisson J, Arnould L, Nambot S, Faivre L, Boidot R, Ghiringhelli F

EBioMedicine. 2020 Jan 7;51:102624

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.

Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O, Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A, Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F

Gut. 2019 Nov 28;:

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.

Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baère T,

Eur. J. Cancer. 2019 Oct 31;123:92-100

A simplified table using validated diagnostic criteria is effective to improve characterization of colorectal polyps: the CONECCT teaching program.

Fabritius M, Gonzalez JM, Becq A, Dray X, Coron E, Brenet-Defour L, Branche J, Gerard R, Lepage C, Poincloux L, Lienhart I, Bonniaud P, Bounnah MT, Rivory J, Lépilliez V, Subtil F, Saurin JC, Ponchon T, Jacques J, Pioche M

Endosc Int Open. 2019 Oct;7(10):E1197-E1206

Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors.

Minon M, Soriano C, Morland D, Walter T, Lepage C, Tabarin A, Deblock M, Rousset P, Barbe C, Hoeffel C, Cadiot G

Endocrine. 2019 Sep 28;:

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J,

Ann. Surg.. 2019 Jul 6;:

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials.

Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, André T, Vernerey D

Cancer Epidemiol. Biomarkers Prev.. 2019 Jul;28(7):1153-1161

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

Bruzzi M, Auclin E, Lo Dico R, Voron T, Karoui M, Espin E, Cianchi F, Weitz J, Buggenhout A, Malafosse R, Denimal F, Le Malicot K, Vernerey D, Douard R, Emile JF, Lepage C, Laurent-Puig P, Taieb J

Ann. Surg. Oncol.. 2019 Jun 17;:

Net survival in recurrence-free colon cancer patients.

Drouillard A, Bouvier AM, Boussari O, Romain G, Manfredi S, Lepage C, Faivre J, Jooste V

Cancer Epidemiol. 2019 Jun 15;61:124-128

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).

Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T,

Radiother Oncol. 2019 Jun 8;140:84-89

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparico T, Hoeffel C,

Gut. 2019 May 17;:

Low cross-reactivity between cisplatin and other platinum salts.

Pasteur J, Favier L, Pernot C, Guerriaud M, Bernigaud C, Lepage C, Jouve JL, Isambert N, Collet E

J Allergy Clin Immunol Pract. 2019 Feb 15;:

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.

Lacas B, Bouché O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, Borget I

Expert Rev Pharmacoecon Outcomes Res. 2019 Feb 9;:

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

Bachet JB, Lucidarme O, Levache CB, Barbier E, Raoul JL, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse JP, Di Fiore F, Etienne PL, Dupuis OJM, Aleba A, Lepage C, Taieb J,

Eur. J. Cancer. 2018 Oct 18;104:108-116

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.

Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O

Gastric Cancer. 2018 Oct 11;:

Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study.

Lapeyre-Prost A, Pernot S, Sigrand J, Mary F, Le Malicot K, Aparicio T, Dahan L, Caroli-Bosc FX, Lecomte T, Racine Doat S, Marthey L, Desrame J, Lepage C, Taieb J

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii160

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8.

Laurent-Puig P, Marisa L, Ayadi M, Blum Y, Balogoun R, Pilati C, Le Malicot K, Lepage C, Emile JF, Salazar R, Aust D, Duval A, Selves J, Guenot D, Milano G, Seitz JF, Taieb J, Boige V, de Reyniès A

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii18

Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study.

Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli Bosc FX, Aparicio T, Bouhier Leporrier K, Hentic Dhome O, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Iwanicki Caron I, Ducreux MP, Lombard Bohas C, de Baere T

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii469

Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer.

Taieb J, Phelip JM, Rinaldi Y, Barbier E, Bouche O, Khemissa Akouz F, Gratet A, Petorin C, Miglianico L, Malka D, Laharie Mineur H, Rebischung C, Lepage C, Francois E, Dahan L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii244

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial.

Gaston Mathe Y, Martin-Lannerée S, Vazart C, Fontaine K, Mulot C, Caumont A, Montestruc F, Le Malicot K, Lepage C, Taieb J, Laurent-Puig P

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii175

Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD.

Aparicio T, Darut Jouve A, Khemissa F, Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C, Falandry C, Duluc M, Rinaldi Y, Legoux JL, Ben Abdelghani M, Assenat E, Dhooge M, Smith D, Des Guetz G, Lepage C

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii156

Very high-risk individuals for colorectal cancer: Local oncologic networks are critically needed!

Manfredi S, Lepage C, Faivre J

Dig Liver Dis. 2018 Sep 21;:

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P

Clin. Cancer Res.. 2018 Jun 19;:

Identification of resources and skills developed by partners of patients with advanced colon cancer: a qualitative study.

Meunier-Beillard N, Ponthier N, Lepage C, Gagnaire A, Gheringuelli F, Bengrine L, Boudrant A, Rambach L, Quipourt V, Devilliers H, Lejeune C

Support Care Cancer. 2018 Jun 5;:

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF,

Eur. J. Cancer. 2018 May 25;98:1-9

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F, Maillard E

Dig Liver Dis. 2018 Mar;50(3):305-307

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J,

J. Clin. Oncol.. 2018 Mar 1;36(7):674-681

Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.

Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, Piron L, Cercueil JP, Loffroy R, Latournerie M, Wendremaire M, Lepage C, Boulin M

J. Hepatol.. 2018 Feb 8;:

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C

Dig Liver Dis. 2018 Feb;50(2):195-198

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A

J. Natl. Cancer Inst.. 2018 Jan 1;110(1):

[Epidemiology of pancreatic cancer].

Drouillard A, Manfredi S, Lepage C, Bouvier AM

Bull Cancer. 2018 Jan;105(1):63-69

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P,

JAMA Oncol. 2017 Nov 22;:

Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population.

Lopez A, Bouvier AM, Jooste V, Cottet V, Romain G, Faivre J, Manfredi S, Lepage C

Gut. 2017 Oct 26;:

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G

Endocrine. 2017 Jun;:

Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status.

Taieb J, Kourie Hampig R, Emile Jean F, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem Jean L, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent Puig P

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii142

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J, ,,,,,,,,,,,,,,,,

Eur. J. Cancer. 2017 Jun;82:16-24

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G,

Eur. J. Cancer. 2017 May;79:158-165

Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.

Sefrioui D, Vermeulin T, Blanchard F, Chapusot C, Beaussire L, Armengol-Debeir L, Sesboué R, Gangloff A, Hebbar M, Copin MC, Houivet E, Schwarz L, Clatot F, Tuech JJ, Bénichou J, Martin L, Bouvier AM, Sabourin JC, Sarafan-Vasseur N, Frébourg T, Lepage C, Michel P, Di Fiore F

Int. J. Cancer. 2017 Apr;140(7):1653-1661

Waldmann's disease: a rare cause of protein losing enteropathy in an adult patient.

Martins CR, Gagnaire A, Rostain F, Lepage C

Rev Esp Enferm Dig. 2017 Apr;109:

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T

Dig Liver Dis. 2017 Mar;:

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

Kientz C, Joly MO, Faivre L, Clemenson A, Dalac S, Lepage C, Chapusot C, Jacquot C, Schiappa R, Lebrun M

Hered Cancer Clin Pract. 2017 ;15:6

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L

Oncotarget. 2017 Jan;8(2):1957-1971

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study.

Lepage C, Bossard N, Dejardin O, Carmona-Garcia MC, Manfredi S, Faivre J,

Eur. J. Cancer Prev.. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S48-S55

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P,

Ann. Oncol.. 2016 Dec;:

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T

Dig Liver Dis. 2016 Nov;48(11):1283-1289

Early Gastric Cancer: Trends in Incidence, Management, and Survival in a Well-Defined French Population.

Chapelle N, Bouvier AM, Manfredi S, Drouillard A, Lepage C, Faivre J, Jooste V

Ann. Surg. Oncol.. 2016 Oct;23(11):3677-83

Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study).

Scoazec JY, Couvelard A, Monges G, Guyétant S, Bisot-Locard S, Parot X, Lepage C,

Neuroendocrinology. 2016 Jul;:

HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer.

Buhard O, Lagrange A, Guilloux A, Colas C, Chouchène M, Wanherdrick K, Coulet F, Guillerm E, Dorard C, Marisa L, Bokhari A, Greene M, El-Murr N, Bodo S, Muleris M, Sourouille I, Svrcek M, Cervera P, Blanché H, Lefevre JH, Parc Y, Lepage C, Chapusot C, Bouvier AM, Gaub MP, Selves J, Garrett K, Iacopetta B, Soong R, Hamelin R, Garrido C, Lascols O, André T, Fléjou JF, Collura A, Duval A

J. Med. Genet.. 2016 Jun;53(6):377-84

DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P

JAMA Oncol. 2016 Jan;:

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P

JAMA Oncol. 2016 Jan;:1-11

Erratum to: Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population.

Chapelle N, Manfredi S, Lepage C, Faivre J, Bouvier AM, Jooste V

Gastric Cancer. 2015 Oct 7.

Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5.

Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, Sant M, Trama A, Faivre J

Eur J Cancer. 2015 Sep 5. pii: S0959-8049(15)00714-5

Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study.

Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, Bouvier AM

Dis Colon Rectum. 2015 Aug;58(8):743-52

Conditional net survival: Relevant prognostic information for colorectal cancer survivors. A French population-based study.

Drouillard A, Bouvier AM, Rollot F, Faivre J, Jooste V, Lepage C

Dig Liver Dis. 2015 Jul;47(7):597-601

[Colorectal cancer surgery with curative intent: what surveillance?].

Drouillard A, Lepage C

Rev Prat. 2015 Jun;65(6):798-801.

[Colorectal cancer: a heterogeneous complex model].

Lepage C

Rev Prat. 2015 Jun;65(6):765-6

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, Pezet D, Baconnier M, Deguiral P, Terrebone E, Adenis A, Le Malicot K, Bedenne L, Bouche O

Dig Liver Dis. 2015 Apr 2. pii: S1590-8658(15)00265-0

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening.

Dancourt V, Hamza S, Manfredi S, Drouillard A, Bidan JM, Faivre J, Lepage C

Eur J Cancer Prev. 2015 Apr 6.

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.

Vadot L, Boulin M, Guiu B, Aho LS, Vourc'h M, Musat A, Hillon P, Lepage C, Guignard MH, Fagnoni P

J Clin Pharm Ther. 2015 Feb;40(1):83-90

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.

Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, Laurent-Puig P

Cancer Med. 2015 Feb 2

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307).

Nuemi G, Devilliers H, Le Malicot K, Guimbaud R, Lepage C, Quantin C

Health Qual Life Outcomes. 2015 Sep 22;13(1):151.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E, André T, Seitz JF, Montérymard C, Arsene D, Volet J, Abakar-Mahamat A, Lecomte T, Guerin-Meyer V, Legoux JL, Deplanque G, Guillet P, Ciccolini J, Lepage C, Dahan L

PLoS ONE. 2015 ;10(8):e0135907

Incidence and survival in late liver metastases of colorectal cancer.

Landreau P, Drouillard A, Launoy G, Ortega-Deballon P, Jooste V, Lepage C, Faivre J, Facy O, Bouvier AM

J. Gastroenterol. Hepatol.. 2015 Jan;30(1):82-5

Trends in the management of gastric cancer over a 32-year period: a French population-based study.

Herbreteau E, Jooste V, Hamza S, Lepage C, Faivre J, Bouvier AM

Gastric Cancer. 2015 Jan;18(1):129-37

Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer.

Hamza S, Cottet V, Touillon N, Dancourt V, Bonithon-Kopp C, Lepage C, Faivre J

Dig Liver Dis. 2014 Dec;46(12):1121-5

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J,

Ann. Oncol.. 2014 Dec;25(12):2378-85

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study.

Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B

Eur J Cancer. 2014 Nov;50(17):2975-82

632PEFFICACY AND SAFETY OF PERIOPERATIVE CHEMOTHERAPY WITH 5FU-CISPLATIN-CETUXIMAB IN GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS (GGOJA): A SINGLE ARM MULTICENTRE PHASE II TRIAL (FFCD 0901).

Mariette C, Piessen G, Monterymard C, Pezet D, Ferru A, Baconnier M, Adhoute X, Tavan D, Lepage C, Bouché O

Ann. Oncol.. 2014 Sep;25(suppl_4):iv216

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM

Dig Liver Dis. 2014 Sep;46(9):854-8

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.

Degrolard-Courcet E, Sokolowska J, Padeano MM, Guiu S, Bronner M, Chery C, Coron F, Lepage C, Chapusot C, Loustalot C, Jouve JL, Hatem C, Ferrant E, Martin L, Coutant C, Baurand A, Couillault G, Delignette A, El Chehadeh S, Lizard S, Arnould L, Fumoleau P, Callier P, Mugneret F, Philippe C, Frebourg T, Jonveaux P, Faivre L

Eur J Hum Genet. 2014 Aug;22(8):979-87

Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.

Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, Bedenne L

Ann. Surg. Oncol.. 2014 Aug;21(8):2636-41

Trends in incidence and management of cancer of the ampulla of Vater.

Rostain F, Hamza S, Drouillard A, Faivre J, Bouvier AM, Lepage C

World J Gastroenterol. 2014 Aug 7;20(29):10144-50

Management of rectal cancer in France in a well-defined population.

Desgrippes R, Bouvier V, Delafosse P, Robaszkiewicz M, Molinie F, Tretarre B, Lepage C, Faivre J, Jooste V, Bouvier AM

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):743-7

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C

Lancet Oncol. 2014 Jul;15(8):862-73

Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.

Boulin M, Hillon P, Cercueil JP, Bonnetain F, Dabakuyo S, Minello A, Jouve JL, Lepage C, Bardou M, Wendremaire M, Guerard P, Denys A, Grandvuillemin A, Chauffert B, Bedenne L, Guiu B

Aliment Pharmacol Ther. 2014 Jun;39(11):1301-13

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.

Boulin M, Adam H, Guiu B, Aho LS, Cercueil JP, Di Martino C, Fagnoni P, Minello A, Jouve JL, Hillon P, Bedenne L, Lepage C

Dig Liver Dis. 2014 Apr;46(4):358-62

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy.

Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, Loh M, Soong R, Zeps N, Platell C, Mews A, Iacopetta B, De Thonel A, Seigneuric R, Marcion G, Chapusot C, Lepage C, Bouvier AM, Gaub MP, Milano G, Selves J, Senet P, Delarue P, Arzouk H, Lacoste C, Coquelle A, Bengrine-Lefevre L, Tournigand C, Lefevre JH, Parc Y, Biard DS, Flejou JF, Garrido C, Duval A

Gastroenterology. 2014 Feb;146(2):401-11.e1.

Adjuvant treatments for gastric cancer: from practice guidelines to clinical practice.

Bouvier AM, Crehange G, Azelie C, Cheynel N, Jouve JL, Bedenne L, Faivre J, Lepage C, Maingon P

Dig Liver Dis. 2014 Jan;46(1):72-5

Immunochemical faecal occult blood tests for colorectal cancer screening: no time to lose.

Lepage C

Dig Liver Dis. 2014 Jan;46(1):30-1

Long-term net survival in patients with colorectal cancer in France: an informative contribution of recent methodology.

Rollot F, Chauvenet M, Roche L, Hamza S, Lepage C, Faivre J, Bouvier AM

Dis Colon Rectum. 2013 Oct;56(10):1118-24

Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?

Mitry E, Rollot F, Jooste V, Guiu B, Lepage C, Ghiringhelli F, Faivre J, Bouvier AM

Eur J Cancer. 2013 Sep;49(13):2919-25

Patterns of recurrence of obstructing colon cancers after surgery for cure: a population-based study.

Cortet M, Grimault A, Cheynel N, Lepage C, Bouvier AM, Faivre J

Colorectal Dis. 2013 Sep;15(9):1100-6

Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.

Hamza S, Dancourt V, Lejeune C, Bidan JM, Lepage C, Faivre J

Eur J Cancer. 2013 Aug;49(12):2727-33

Epidemiology and risk factors for oesophageal adenocarcinoma.

Lepage C, Drouillard A, Jouve JL, Faivre J

Dig Liver Dis. 2013 Aug;45(8):625-9

Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.

Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, Hillon P, Chauffert B, Krause D, Guiu B

Cardiovasc Intervent Radiol. 2013 Aug;36(4):1039-46

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

Lepage C, Bouvier AM, Faivre J

Eur J Endocrinol. 2013 Mar 15;168(4):R77-83

Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study.

Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J, Gatta G, Capocaccia R, Sant M, Baili P, Lombardo C, Aareleid T, Ardanaz E, Bielska-Lasota M, Bolick S, Cress R, Elferink M, Fulton JP, Galceran J, Gozdz S, Hakulinen T, Primic-Zakelj M, Rachtan J, Diba CS, Sanchez MJ, Schymura MJ, Shen T, Tagliabue G, Tumino R, Vercelli M, Wolf HJ, Wu XC, Coleman MP

BMJ Open. 2013 Sep 10;3(9):e003055

Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008).

Peyrin-Biroulet L, Lepage C, Jooste V, Gueant JL, Faivre J, Bouvier AM

Inflamm Bowel Dis. 2012 Dec;18(12):2247-51

Faecal immunochemical tests: a valuable tool for colorectal cancer screening.

Lepage C, Hamza S

Dig Liver Dis. 2012 Aug;44(8):629-30

Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002.

Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C

Eur J Cancer. 2012 Jul;48(10):1417-24

Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

Guiu B, Crevisy-Girod E, Binquet C, Duvillard L, Masson D, Lepage C, Hamza S, Krause D, Verges B, Minello A, Cercueil JP, Hillon P, Petit JM

Eur Radiol. 2012 Apr;22(4):855-63

Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method.

Tournier B, Chapusot C, Courcet E, Martin L, Lepage C, Faivre J, Piard F

BMC Cancer. 2012 Jan 13;12:12.

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

Boulin M, Ciboulet A, Guiu B, Maillard E, Bonnetain F, Minello A, Gagnaire A, Lepage C, Krause D, Hillon P, Bedenne L, Cercueil JP, Chauffert B, Jouve JL

Dig Liver Dis. 2011 Nov;43(11):905-11